par Kenemans, Peter;Bundred, Nigel J;Foidart, Jean-Michel;Kubista, Ernst;von Schoultz, Bo;Sismondi, Piero;Vassilopoulou-Sellin, Rena;Yip, Cheng Har;Egberts, Jan;Mol-Arts, Mirjam;Mulder, Roel;van Os, Bertil;Beckmann, Matthias W;Simon, Philippe
Référence Lancet oncology, 10, 2, page (135-146)
Publication Publié, 2009-02
Référence Lancet oncology, 10, 2, page (135-146)
Publication Publié, 2009-02
Article révisé par les pairs
Résumé : | Vasomotor symptoms and bone loss are complications frequently induced by adjuvant treatment for breast cancer. Tibolone prevents both side-effects, but its effect on cancer recurrence is unknown. The aim of this study was to show non-inferiority of tibolone to placebo regarding risk of recurrence in breast-cancer patients with climacteric complaints. |